Bioindustry LIM

What Bioindustry LIM does

Bioindustria L.I.M. SpA is a privately held Italian pharmaceutical manufacturer founded in 1932 and headquartered in Novi Ligure, in the Piedmont region. The company operates three divisions across two manufacturing sites: a Pharma Division producing generic sterile (injectable and freeze-dried) and non-sterile (tablets, capsules) medicines at Novi Ligure; an API Division at Fresonara covering approximately 20,000 square meters and producing Active Pharmaceutical Ingredients (diuretics, anti-hypertensives, selective alpha-blockers, antihistamines, bisphosphonates) under cGMP; and a Preparati Industriali division producing magistral preparations (Copper Histidinate, Calcium Gluconate, Hyaluronidase) sold directly to licensed physicians.

The company's revenue mechanics span four streams: sale of finished generic pharmaceutical products to hospitals, healthcare facilities, and home-therapy patients in Italy and abroad; API supply to third-party pharmaceutical companies globally; industrial compounded magistral preparations under Italian Decree 219/2006; and third-party contract manufacturing for European and extra-European clients. Distribution is via direct B2B institutional sales; there is no retail or consumer channel. Pricing is not publicly disclosed for most products, with one magistral product publicly listed at €135 per package.

Manufacturing capability is supported by on-site Chemical and Microbiological Quality Control laboratories (HPLC, GC, AAS, NIR, FT-IR, UV-VIS, osmometry), an R&D pilot installation up to 30 liters for new synthesis methods, and a broad organic synthesis reaction portfolio. Capital is €1,393,200 paid-in, with 51-100 employees. The company maintains cGMP compliance audited by AIFA, FDA (inspected since 2013, last inspection 2018 with no Form 483 issued), and Minzdrav Rossii, and pursues R&D collaborations with the Universities of Milan, Rome, Pavia, and Genoa.

Name

Bioindustry LIM

Legal name

Bioindustria L.I.M. SpA

Website

https://bioindustrialim.it

Company type

Private

Founded year

1932

Operating status

Operating

Headcount range

51–100 employees

Short description

Bioindustria L.I.M. SpA is an Italian, privately held pharmaceutical manufacturer founded in 1932, producing generic injectables, APIs, and magistral preparations at its Novi Ligure and Fresonara plants for hospitals, international pharma companies, and home-therapy patients.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Sterile injectable production
• Lyophilised drug products
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Novi Ligure

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Others

Revenue model

1. Finished Pharmaceutical Products: Manufacturing and sale of generic pharmaceutical products including sterile injectables (small and large volume solutions, freeze-dried products) and non-sterile products (tablets and capsules) for domestic and international markets.
2. Active Pharmaceutical Ingredients (APIs): Production of APIs for internal use and sale to third-party pharmaceutical companies globally. APIs include diuretics, anti-hypertensives, selective alpha-blockers, antihistamines, and bisphosphonates.
3. Industrially Compounded Medicinal Products: Production of industrial magistral preparations (Rame Istidinato, Calcio Gluconato, Jaluronidasi Bioindustria) sold directly to licensed physicians for use on identified patients.
4. Contract Manufacturing (Third-Party): Manufacturing pharmaceutical products for third-party clients, both development projects and established products, serving European and extra-European markets.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Bioindustria L.I.M. manufactures generic pharmaceutical products — sterile injectable solutions, lyophilised products, tablets, and capsules — at its Novi Ligure plant, and Active Pharmaceutical Ingredients (APIs) at its Fresonara plant. The company also produces industrial magistral preparations (Rame Istidinato, Calcio Gluconato, Jaluronidasi Bioindustria) for licensed physicians and offers contract manufacturing services to third-party pharmaceutical clients.

Differentiator

Problem solved

Functional benefit

Brands

• Divisione Pharma: Pharma division producing generic pharmaceutical products including sterile and non-sterile medicines at the Novi Ligure plant
• Divisione API
• Preparati industriali
• Jaluronidasi Bioindustria

Products and services

• Generic Pharmaceutical Products — Sterile Injectables (Divisione Pharma) Sterile injectable generic pharmaceutical products manufactured at the Novi Ligure plant for Italian and international hospitals and home therapy patients, including large-volume solutions in glass bottles, small-volume solutions in vials/ampoules, and freeze-dried (lyophilised) products.
• Non-Sterile Generic Pharmaceutical Products — Tablets and Capsules (Divisione Pharma) Non-sterile generic pharmaceutical products — tablets and capsules — manufactured at the Novi Ligure plant for the Italian and international generic pharmaceutical markets.
• Active Pharmaceutical Ingredients (API Division) cGMP-compliant Active Pharmaceutical Ingredients (APIs) produced at the Fresonara plant for internal use and sale to third-party pharmaceutical companies globally; includes diuretics, anti-hypertensives, selective alpha-blockers, antihistamines, and bisphosphonates. The Fresonara API plant occupies approximately 20,000 square meters and is integrated with an AIA environmental authorization.
• Contract Manufacturing for Third-Party Pharmaceutical Clients Contract manufacturing services for third-party pharmaceutical companies covering both development-stage products and established commercial products, executed at Bioindustria's Novi Ligure and Fresonara cGMP facilities for European and extra-European clients.
• Industrial Magistral Preparations (Preparati Industriali) Industrially compounded magistral preparations — including Rame Istidinato (Copper Histidinate), Calcio Gluconato (Calcium Gluconate), and Jaluronidasi Bioindustria (Hyaluronidase) — sold exclusively to licensed physicians in Italy for administration to identified patients, with anticipatory bank transfer payment.

Quantifiable outcome

• FDA inspection in 2018 concluded with no Form 483 observations issued
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• EgualiaminorOthersIndustry association representing generic pharmaceutical companies in Italy. Listed as a partnership logo on the company website.
• CPA (Chemical Pharmaceutical Association)minorOthersChemical Pharmaceutical Association representing pharmaceutical industry interests. Listed as a partnership logo on the company website.
• Confindustria AlessandriaminorOthersLocal employers' association (Confindustria) representing industrial companies in the Alessandria province. Listed as a partnership logo on the company website.
• University of MilancoreStrategic or Co-development PartnerCollaborative R&D partnership in Organic Chemistry and Biochemistry Research. One of several university partnerships contributing to the company's research capabilities.
• University of RomecoreStrategic or Co-development PartnerCollaborative R&D partnership in Organic Chemistry and Biochemistry Research. Contributing to innovation in traditional manufacturing processes.
• University of PaviacoreStrategic or Co-development PartnerCollaborative R&D partnership in Organic Chemistry and Biochemistry Research. Long tradition of collaboration in research.
• University of GenoacoreStrategic or Co-development PartnerCollaborative R&D partnership in Organic Chemistry and Biochemistry Research. Long tradition of collaboration in research.

Scale indicators4 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• ACS Dobfar: Italian-headquartered API and finished sterile injectable manufacturer with cGMP-certified facilities serving global pharmaceutical markets. Closely comparable as an Italian peer operating across API synthesis and sterile injectable contract manufacturing for third parties.
• Alfasigma: Italian privately-held pharmaceutical company with a broad portfolio of branded and generic specialty pharma products and significant manufacturing infrastructure in Italy. Highly comparable as a domestic Italian peer operating across branded specialty, generic, and contract manufacturing in similar therapeutic areas.
• Chiesi Farmaceutici: Private Italian pharmaceutical group with manufacturing operations and a portfolio spanning multiple therapeutic areas including hospital products. Comparable as a family-controlled Italian pharma with integrated manufacturing capabilities and international export presence.
• Recipharm: Swedish-headquartered contract development and manufacturing organization (CDMO) with multiple European sites specializing in sterile injectables, APIs, and finished dose manufacturing. Closely comparable as a European CDMO competitor targeting similar third-party pharma clients.
• Cambrex: US-headquartered CDMO specializing in API development and manufacturing with multiple sites including European facilities. Comparable as an API-focused contract manufacturer serving global generic and innovator pharma clients across regulated markets.
• Zambon: Italian multinational pharmaceutical company with a presence in branded pharma, generics, and chemical synthesis (including APIs through its Zambon Chemicals division). Comparable as an Italian pharma with vertically integrated chemistry and finished dose operations.

Broad incumbents

• Menarini Group: Italy's largest pharmaceutical company, headquartered in Florence, with a broad portfolio spanning branded specialty, generics, diagnostics, and biopharma across 140+ markets. Comparable as a large Italian pharma incumbent with manufacturing infrastructure that competes in overlapping therapeutic categories.
• Sandoz (Novartis): Global leader in generic pharmaceuticals and biosimilars with extensive sterile injectable manufacturing capacity. Comparable as a large-scale generic injectable incumbent competing for the same hospital and international pharmaceutical supply contracts.
• Hospira / Pfizer CentreOne: Pfizer's contract manufacturing arm (originating from Hospira, the historic leader in sterile injectable generics). Comparable as a dominant global player in sterile injectable manufacturing, contract manufacturing, and API supply targeting the same hospital and pharma company customers.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with leading positions in sterile injectables, APIs, and oral generics globally. Comparable as a generic injectable incumbent dominating the same hospital tender and contract manufacturing markets Bioindustria L.I.M. participates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bioindustria-laboratorio-italiano-medicinali-s.p.a.-siglabile-bioindustria-l.i.m.-s.p.a.-

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioindustry LIM